Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes

Uddhav P Kelavkar1, Justin Hutzley, Kevin McHugh

  • 1Division of Hematology/Oncology and Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA. kelavkarup@upmc.edu

Neoplasia (New York, N.Y.)
|July 2, 2009
PubMed

Insights

Omega-3 fatty acids, specifically stearidonic acid (SDA), significantly slow prostate cancer growth by altering omega-6/omega-3 ratios and promoting apoptosis. Dietary omega-6 linoleic acid (LA) accelerates tumor growth, while switching to omega-3 SDA reverses this effect.

Area of Science:

  • Nutritional Oncology
  • Cancer Metabolism
  • Molecular Biology

Background:

  • Prostate cancer growth is influenced by dietary fatty acids.
  • Omega-6 polyunsaturated fatty acids (PUFAs) and their metabolites can promote cancer progression.
  • Omega-3 PUFAs are investigated for their potential anti-cancer effects.

Purpose of the Study:

  • To determine omega-3 (omega-3) bioavailability to prostate tumors.
  • To elucidate the mechanisms by which omega-3 fatty acids affect tumor growth.
  • To assess the feasibility of targeting 15-lipoxygenase-1 (15-LO-1) and cyclooxygenase-2 (COX-2) pathways with omega-3 and omega-6 PUFAs.

Main Methods:

  • Nude mice bearing LAPC-4 prostate cancer xenografts were fed diets high in omega-6 linoleic acid (LA), omega-3 stearidonic acid (SDA), or a control diet.
  • Tumor growth, apoptosis, proliferation (Ki-67), and lipid profiles were analyzed.
  • Enzyme activities (15-LO-1, COX-2, elongase, desaturases) and fatty acid ratios (omega-6/omega-3) in tumor tissues were measured using high-performance liquid chromatography.

Main Results:

  • Tumors from mice fed the LA diet exhibited the most rapid growth, while SDA diet-fed mice showed significantly slower growth and increased apoptosis.
  • Switching from an LA to an SDA diet decreased tumor growth, whereas switching from SDA to LA accelerated it.
  • The omega-6/omega-3 ratio was significantly higher in tumors from LA-fed mice and lower in SDA-fed mice, correlating with enzyme activities and proliferation/apoptosis markers.

Conclusions:

  • Dietary omega-3 fatty acids, particularly SDA, can inhibit prostate cancer growth by favorably altering the tumor's omega-6/omega-3 ratio.
  • Omega-3 fatty acids promote apoptosis and inhibit proliferation in tumors, potentially by competing with omega-6 fatty acids for 15-LO-1 and COX-2 pathways.
  • These findings support the mechanistic role of dietary fatty acids in modulating prostate cancer progression and suggest therapeutic potential for omega-3 supplementation.